Effectiveness of Niclosamide as Add-on Therapy to the Standard of Care Measures in COVID-19 Management (Randomized Controlled Clinical Trial)
试验速览
- 阶段
- 2 期
- 入组人数
- 150
- 试验地点
- 1
- 主要终点
- Time to recovery
研究概览
简要总结
Assessment of the Effectiveness of Niclosamide as Add on Therapy to the Standard of care Measures in COVID-19 Management in a randomized controlled clinical trial
详细描述
Protocol of therapy Niclosamaide Add on group
- NCS 2 grams orally loading dose chewable then 1g every 8 hours in the first day, then on the 2nd day 1g x3 for 7 days. [ this means only in the first day 4 gm/d then on the second day 3g/d in 3 divided doses for 7 days]
- If the participant requires mechanical ventilation over the course of the study, NGT may be administered via nasogastric (NG) or orogastric (OG) tube and, if possible, should be administered with a scheduled nasogastric (NG) or orogastric (OG) feeding.
Control group The patients in this group will receive only standard care which will include all or some of the following, according to the clinical condition of each patient:
- Acetaminophen 500mg on need
- Vitamin C 1000mg twice/ day
- Zinc 75-125 mg/day
- Vitamin D3 5000IU/day
- Azithromycin 250mg/day for 5 days
- Oxygen therapy/ C-Pap if needed
- Dexamethasone 6 mg/day or methylprednisolone 40mg twice per day, if needed
- Mechanical ventilation, if needed
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with age above 18 years and of any gender.
- •Definite diagnosis of COVID-19 according to the WHO classification criteria ( 18).
- •Patients symptomatic for no more than three days for mild-moderate cases, no more than two days after being severe cases, and no more than one day after being critical cases.
- •Understands and agrees to comply with planned study procedures.
排除标准
- •Patients refuse to enrol in the study
- •Patients with hypersensitivity or severe adverse effects to niclosamide
- •Renal impairment
- •Hepatic impairment
- •Pregnancy or a desire to become pregnant
- •Breast feeding
研究组 & 干预措施
Niclosamide group: NCS group
NCL + standard therapy
干预措施: Niclosamide Oral Tablet (Drug)
结局指标
主要结局
Time to recovery
时间窗: 7 days
- to study the time to recovery ( stay days in hospital)
Percentage of Cure of the patient
时间窗: 7 days
To assess the percentage of cure of the patient and evaluated by normalization of clinical evaluation, laboratory investigations, and imaging.
次要结局
- The percentage of Progressive patients(7 days)
- Rate of mortality(7 days)
- Side effects(7 days)
研究者
Faiq Gorial
Professor
University of Baghdad
